Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults.
AFLD
Fatty liver disease
Liver function
NAFLD
NHANES
PFAS
PFHxS
PFOA
PFOS
Per- and polyfluoroalkyl substances
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
03
12
2022
accepted:
17
01
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Per- and polyfluoroalkyl substances (PFAS) are widespread pollutants with demonstrated hepatotoxicity. Few studies have examined the association between PFAS and fatty liver disease (FLD) risk in an adult population. In this cross-sectional study of participants from the 2017-2018 National Health and Nutrition Examination Survey, serum PFAS were measured, and FLD cases were ascertained by vibration-controlled transient elastography. Logistic regression models were used to examine the association between circulating PFAS levels and FLD risk. Analyses were stratified into non-alcoholic FLD and alcoholic FLD risk groups by alcohol intake status, as well as controlling for other risk factors, including personal demographics, lifestyle factors, and related health factors. Among 1,135 eligible participants, 446 had FLD. For FLD risk, the multivariable-adjusted odds ratio per log-transformed SD increase (OR Higher serum PFAS was moderately associated with FLD risk and worse liver function in the general population, and among those with independent risk factors, including heavy alcohol intake, obesity, or high-fat diets, PFAS increased the risk. These results suggest synergistic effects on hepatic steatosis between PFAS exposures as measured through biomonitoring data and lifestyle risk factors in a nationally representative US population. The per- and polyfluoroalkyl substances (PFAS) may convey higher risk for chronic liver disease in humans. Among 1,135 US adults in the 2017-2018 National Health and Nutrition Examination Survey, we found that higher serum PFAS was associated with higher fatty liver disease risk and worse liver function, especially among those with liver disease risk factors, including heavy alcohol intake, obesity, or high-fat diets. Continuously monitoring PFAS in the population and examining how they potentiate risk to the liver are essential.
Sections du résumé
Background & Aims
UNASSIGNED
Per- and polyfluoroalkyl substances (PFAS) are widespread pollutants with demonstrated hepatotoxicity. Few studies have examined the association between PFAS and fatty liver disease (FLD) risk in an adult population.
Methods
UNASSIGNED
In this cross-sectional study of participants from the 2017-2018 National Health and Nutrition Examination Survey, serum PFAS were measured, and FLD cases were ascertained by vibration-controlled transient elastography. Logistic regression models were used to examine the association between circulating PFAS levels and FLD risk. Analyses were stratified into non-alcoholic FLD and alcoholic FLD risk groups by alcohol intake status, as well as controlling for other risk factors, including personal demographics, lifestyle factors, and related health factors.
Results
UNASSIGNED
Among 1,135 eligible participants, 446 had FLD. For FLD risk, the multivariable-adjusted odds ratio per log-transformed SD increase (OR
Conclusions
UNASSIGNED
Higher serum PFAS was moderately associated with FLD risk and worse liver function in the general population, and among those with independent risk factors, including heavy alcohol intake, obesity, or high-fat diets, PFAS increased the risk. These results suggest synergistic effects on hepatic steatosis between PFAS exposures as measured through biomonitoring data and lifestyle risk factors in a nationally representative US population.
Impact and Implications
UNASSIGNED
The per- and polyfluoroalkyl substances (PFAS) may convey higher risk for chronic liver disease in humans. Among 1,135 US adults in the 2017-2018 National Health and Nutrition Examination Survey, we found that higher serum PFAS was associated with higher fatty liver disease risk and worse liver function, especially among those with liver disease risk factors, including heavy alcohol intake, obesity, or high-fat diets. Continuously monitoring PFAS in the population and examining how they potentiate risk to the liver are essential.
Identifiants
pubmed: 36968216
doi: 10.1016/j.jhepr.2023.100694
pii: S2589-5559(23)00025-3
pmc: PMC10033989
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100694Subventions
Organisme : NCI NIH HHS
ID : U01 CA259208
Pays : United States
Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
AD has provided volunteer and paid consultation support for populations with PFAS-contaminated water that seek medical monitoring. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Environ Sci Process Impacts. 2019 Nov 1;21(11):1835-1851
pubmed: 31576380
Sci Total Environ. 2019 Feb 25;653:74-81
pubmed: 30408670
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
Environ Int. 2020 Jan;134:105220
pubmed: 31744629
Genes (Basel). 2021 Apr 26;12(5):
pubmed: 33926085
Occup Environ Med. 2018 Jan;75(1):46-51
pubmed: 29133598
Sci Total Environ. 2022 Dec 1;850:158036
pubmed: 35973530
Am J Gastroenterol. 2017 Jan;112(1):18-35
pubmed: 27995906
Front Pharmacol. 2012 Apr 03;3:55
pubmed: 22493581
Science. 2022 Feb 4;375(6580):eabg9065
pubmed: 35113710
Crit Rev Toxicol. 2021 Feb;51(2):141-164
pubmed: 33853480
Environ Int. 2020 Dec;145:106091
pubmed: 32892005
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
Environ Res. 2015 Jan;136:8-14
pubmed: 25460614
Environ Res. 2021 May;196:110361
pubmed: 33131681
Environ Health Perspect. 2022 Apr;130(4):46001
pubmed: 35475652
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386
pubmed: 31024089
J Hepatol. 2018 Feb;68(2):305-315
pubmed: 29154965
Endocrinology. 2021 Dec 1;162(12):
pubmed: 34480479
Curr Environ Health Rep. 2019 Sep;6(3):95-104
pubmed: 31090041
Hepatology. 2022 Jun;75(6):1491-1506
pubmed: 34668597
Clin Mol Hepatol. 2012 Dec;18(4):383-90
pubmed: 23323254
Environ Toxicol Chem. 2021 Mar;40(3):606-630
pubmed: 33017053
Environ Int. 2018 Aug;117:196-203
pubmed: 29754000
Environ Sci Process Impacts. 2020 Dec 1;22(12):2345-2373
pubmed: 33125022
Vital Health Stat 2. 2013 Sep;(161):1-24
pubmed: 25090154
Prev Med. 2022 Jan;154:106903
pubmed: 34861339
Biomedicines. 2019 Dec 13;7(4):
pubmed: 31847084
Environ Health. 2015 Jul 10;14:60
pubmed: 26159541
Am J Gastroenterol. 2010 Jun;105(6):1354-63
pubmed: 20010922
Hepatol Commun. 2020 Apr 04;4(6):890-903
pubmed: 32490324
J Family Med Prim Care. 2020 Jan 28;9(1):390-394
pubmed: 32110624
Environ Health Perspect. 2010 Dec;118(12):1735-42
pubmed: 21126940
Environ Int. 2021 Mar;148:106375
pubmed: 33482440
Environ Res. 2019 Jul;174:143-151
pubmed: 31077989
Environ Int. 2013 Sep;59:354-62
pubmed: 23892228
Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2
pubmed: 29705261
J Occup Environ Med. 2019 Apr;61(4):293-302
pubmed: 30589657
J Hepatol. 2022 Feb;76(2):283-293
pubmed: 34627976
Environ Pollut. 2022 Oct 15;311:119915
pubmed: 35970346
Sci Rep. 2016 Aug 03;6:31006
pubmed: 27484402
JHEP Rep. 2022 Aug 08;4(10):100550
pubmed: 36111068
Ultrasound Med Biol. 2010 Nov;36(11):1825-35
pubmed: 20870345
Endocr Pract. 2022 May;28(5):528-562
pubmed: 35569886
Environ Int. 2020 Dec;145:106099
pubmed: 32916415